Close Menu

Editor's Pick

Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.

The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.

At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.

Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.

A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.

Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.

After a study showed that patients who received guidance from Perthera's tumor board lived longer than those who didn't, the company wants to make its technology more accessible.

With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.

The foundation-funded initiative from Jackson Laboratories has advanced a model for educating oncologists and providing access to tumor genomic profiling in the community setting.

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

Pages